专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

US07486989B2 Device for delivery of oxidizing agents to barrier membranes 有权
标题翻译：用于将氧化剂输送到阻隔膜的装置
公开(公告)号：US07486989B2
公开(公告)日：2009-02-03
申请号：US10609849
申请日：2003-06-30
申请人： Ying Sun , Jue-Chen Liu , Jeffrey M. Wu
发明人： Ying Sun , Jue-Chen Liu , Jeffrey M. Wu
IPC分类号： A61N1/30 , A61M31/00
CPC分类号： A61N1/30
摘要： The present invention features a method of treating infection in a barrier membrane by applying to the membrane a device having a barrier membrane contacting surface that administers an oxidizing agent to the barrier membrane, wherein the device contains: a power source; a first conductive electrode, wherein the first conductive electrode is an inert anode; a second conductive electrode, wherein the second conductive electrode is a cathode; and a carrier containing water; wherein the power source is in electric communication with the first conductive electrode and the second conductive electrode, wherein the first conductive electrode is in ionic communication with the carrier, wherein the oxidizing agent is generated by electric current passing from the first conductive electrode through the carrier, and wherein the carrier is in communication with the barrier membrane contacting surface.
摘要翻译：本发明的特征在于一种通过向隔膜施加具有向隔离膜施用氧化剂的阻挡膜接触表面的装置来处理隔离膜中的感染的方法，其中所述装置包含：电源; 第一导电电极，其中所述第一导电电极是惰性阳极; 第二导电电极，其中所述第二导电电极是阴极; 和含水的载体; 其中所述电源与所述第一导电电极和所述第二导电电极电连通，其中所述第一导电电极与所述载体离子连通，其中所述氧化剂通过从所述第一导电电极通过所述载体的电流产生，并且其中所述载体与所述阻隔膜接触表面连通。

82. 发明申请

US20090005659A1 Tissue Ablation by Shear Force for Sampling Biological Fluids and Delivering Active Agents 审中-公开
标题翻译：通过剪切力抽取生物流体和提供活性剂的组织消融
公开(公告)号：US20090005659A1
公开(公告)日：2009-01-01
申请号：US12181192
申请日：2008-07-28
申请人： Nikiforos Kollias , Ying Sun , Coston Anthony F.
发明人： Nikiforos Kollias , Ying Sun , Coston Anthony F.
IPC分类号： A61B5/00 , A61N1/30
CPC分类号： A61N1/303
摘要： A shear device for use in transporting a molecule through a mammal's mammalian barrier membrane of at least one layer of cells includes a sheet containing an opening(s) and a shear member(s). The sheet is configured for contacting the mammalian barrier membrane (e.g., human skin) and the shear member is configured for ablating a portion of the mammalian barrier membrane forced through the opening(s). This ablating is accomplished by movement of the shear member(s) over the sheet and the opening(s). The ablation of the portion of the mammalian barrier membrane is such that a driving force can be employed to transport the molecule therethrough.
摘要翻译：用于通过哺乳动物的至少一层细胞的哺乳动物屏障膜输送分子的剪切装置包括含有开口和剪切构件的片材。该片被配置用于接触哺乳动物屏障膜（例如，人皮肤），并且剪切构件被配置用于烧蚀被迫穿过开口的哺乳动物屏障膜的一部分。这种消融是通过剪切构件在片材和开口上的移动来实现的。哺乳动物屏障膜部分的消融使得可以采用驱动力来输送分子。

83. 发明授权

US07419962B2 3,6-bicyclolides 有权
标题翻译： 3,6-双环氯化物
公开(公告)号：US07419962B2
公开(公告)日：2008-09-02
申请号：US11295736
申请日：2005-12-06
申请人： Yat Sun Or , Datong Tang , Ying Sun , Yonghua Gai , Guoyou Xu , Zhe Wang
发明人： Yat Sun Or , Datong Tang , Ying Sun , Yonghua Gai , Guoyou Xu , Zhe Wang
IPC分类号： A61K31/70 , C07H17/08
CPC分类号： C07H17/08
摘要： The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
摘要翻译：本发明公开了具有抗菌性质的式（I）化合物或其药学上可接受的盐，酯或前药。本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。本发明还包括制备本发明化合物的方法。

84. 发明申请

US20080125444A1 ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS 失效
标题翻译： ACYCLIC OXIMYL HEPATITIS C蛋白酶抑制剂
公开(公告)号：US20080125444A1
公开(公告)日：2008-05-29
申请号：US11758901
申请日：2007-06-06
申请人： Ying Sun , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Yat Sun Or , Zhe Wang
IPC分类号： A61K31/497 , A61K31/4015 , A61K31/4025 , C07D207/12 , C07D403/12 , C12N7/06 , C07D405/12 , C07D401/14 , A61P31/12 , A61K31/4375
CPC分类号： C07D207/12 , A61K38/00 , C07D207/16 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D471/04 , C07K5/0812
摘要： The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

85. 发明申请

US20070281884A1 Macrocyclic oximyl hepatitis C protease inhibitors 审中-公开
标题翻译：大环肟基丙型肝炎蛋白酶抑制剂
公开(公告)号：US20070281884A1
公开(公告)日：2007-12-06
申请号：US11502740
申请日：2006-08-11
申请人： Ying Sun , Deqiang Niu , Guoyou Xu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Deqiang Niu , Guoyou Xu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/12 , A61K31/395 , C07K5/12
CPC分类号： A61K38/212 , A61K38/12 , A61K38/215 , C07K5/0804 , A61K2300/00
摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

86. 发明授权

US07273851B2 Tri-peptide hepatitis C serine protease inhibitors 有权
标题翻译：三肽丙型肝炎丝氨酸蛋白酶抑制剂
公开(公告)号：US07273851B2
公开(公告)日：2007-09-25
申请号：US10849107
申请日：2004-05-19
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat S. Or
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat S. Or
IPC分类号： A61K38/00
CPC分类号： C07K5/0808 , A61K38/00
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

87. 发明授权

US07229972B2 3,6-Bicyclolides 有权
标题翻译： 3,6-双环化合物
公开(公告)号：US07229972B2
公开(公告)日：2007-06-12
申请号：US11008581
申请日：2004-12-07
申请人： Yat Sun Or , Datong Tang , Yonghua Gai , Ying Sun , Guoyou Xu , Zhe Wang
发明人： Yat Sun Or , Datong Tang , Yonghua Gai , Ying Sun , Guoyou Xu , Zhe Wang
IPC分类号： A61K31/70 , C07H17/08
CPC分类号： C07H17/08
摘要： The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
摘要翻译：本发明公开了具有抗菌性质的式（I）化合物或其药学上可接受的盐，酯或前药。本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。本发明还包括制备本发明化合物的方法。

88. 发明申请

US20070060510A1 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors 有权
标题翻译：喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂
公开(公告)号：US20070060510A1
公开(公告)日：2007-03-15
申请号：US11489011
申请日：2006-07-18
申请人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Or , Zhe Wang
发明人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Or , Zhe Wang
IPC分类号： A61K38/12 , A61K31/497 , C07K5/12 , C07D487/14
CPC分类号： C07K5/0802 , A61K38/212 , A61K38/215 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I或II化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

89. 发明申请

US20070049901A1 Method of treating acne with stratum corneum piercing device 审中-公开
标题翻译：用角质层穿刺装置治疗痤疮的方法
公开(公告)号：US20070049901A1
公开(公告)日：2007-03-01
申请号：US11409454
申请日：2006-04-21
申请人： Jeffrey Wu , Jue Liu , Ying Sun , Justin McDonough , Danilo Lambino , Mariam Maghribi
发明人： Jeffrey Wu , Jue Liu , Ying Sun , Justin McDonough , Danilo Lambino , Mariam Maghribi
IPC分类号： A61M31/00
CPC分类号： A61M37/0015 , A61B2017/00765 , A61M37/00 , A61M2037/0023 , A61M2037/0046 , A61N1/306 , A61N1/325
摘要： The invention features a method of treating acne by piercing the stratum corneum of skin in need of such treatment with a stratum corneum-piercing device that contains at east one stratum corneum-piercing microprotrusion and a compressible cover such that the compressible cover substantially encases the at least one stratum corneum-piercing microprotrusion, and wherein upon contacting the skin with the compressible cover, the at least one stratum corneum-piercing microprotrusion protrudes from the compressible cover and pierces the stratum corneum of the skin.
摘要翻译：本发明的特征在于一种通过用东方一角质层穿刺微灌注的角质层刺穿装置刺穿需要这种治疗的皮肤角质层来治疗痤疮的方法，使得可压缩盖基本上包围在至少一个角质层刺穿微灌注，并且其中当使皮肤与可压缩覆盖层接触时，至少一个角质层刺穿的微量突出从可压缩盖突出并刺穿皮肤的角质层。

90. 发明申请

US20070014489A1 Nonrigid registration of cardiac perfusion MR images using adaptive local template matching 失效
标题翻译：使用自适应局部模板匹配的心脏灌注MR图像的非刚性注册
公开(公告)号：US20070014489A1
公开(公告)日：2007-01-18
申请号：US11365273
申请日：2006-03-01
申请人： Ying Sun , Gareth Funka-Lea
发明人： Ying Sun , Gareth Funka-Lea
IPC分类号： G06K9/32 , G06K9/00
CPC分类号： G06T7/20 , G06T7/0012 , G06T2207/30048
摘要： Motion of the heart during contrast enhancement is modeled at two hierarchical levels: global translation and local deformation. Large-scale, i.e., global, translational motion is identified using global template matching, while the local deformation of a portion of the object (e.g., the left ventricle where the object is a heart) is obtained using an adaptive local template matching scheme which adapts to the local edge distributions by varying the height and the width of the template as well as the location of the template followed by spatial regularization. To address the difficulty of rapid intensity changes across the image sequence as the contrast agent perfuse into the tissue, an edge-based similarity measure is used for template matching.
摘要翻译：在对比度增强过程中心脏的运动被建模在两个层次上：全局平移和局部变形。使用全局模板匹配来确定大规模，即全局，平移运动，而使用自适应局部模板匹配方案获得对象部分（例如，对象是心脏的左心室）的局部变形，通过改变模板的高度和宽度以及模板的位置跟随空间正则化来适应局部边缘分布。为了解决造影剂灌注到组织中的图像序列之间的快速强度变化的难度，使用基于边缘的相似性度量来进行模板匹配。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式